Side-by-side · Research reference

CrystagenvsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BHuman-MechanisticAUTO-DRAFTED11/40 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

Crystagen

Selank

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

Selank

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

150–300 mcg / dose intranasalZaderej 2014

Evidence basis

Animal / mechanistic

Human-mechanistic + Russian clinical trialsMedvedev 2007

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

2–3× per day during stress

Duration

Unknown — chronic administration presumed in animal models

10–14 day cycles, repeated as needed

Half-life

Not reported

Short (minutes plasma); CNS effect lasts ~3 hr

Lower / starter dose

—

75 mcg / dose

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon preferred

04Side Effects & Safety

Parameter

Crystagen

Selank

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

Crystagen

Selank

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Caveat

—

Avoid co-administration with strong sedatives or other anxiolytics initially.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Selank

— no documented stacks